Newsletter Subject

Are You Committing This Common Trading Pitfall?

From

biotechbreakouts.com

Email Address

kyle@biotechbreakouts.com

Sent On

Fri, May 8, 2020 05:18 PM

Email Preheader Text

Hello Undefined, When I first started trading, I only had $15K to trade with… and fast forward

Hello Undefined, When I first started trading, I only had $15K to trade with… and fast forward to today, I’ve generated more than $8,000,000 in career trading profits — and more than $1,000,000 in 2020 alone. The thing is, it wasn’t just a straight shot to profitability for me. In fact, I made a lot of common mistakes… and that led me to lose approximately half of my $15K account. It wasn’t [until I went back to figure out what I was doing right and wrong]( — that I discovered what was eating at my account. It’s one common pitfall I believe traders should avoid at all costs… and it’s known as: Style Drifting What’s style drifting? I believe it’s the number one factor that can ruin accounts. If you diverge from your trading objective or strategies, then you would be considered a “style drifter”. Think about it like this, mixed martial arts fighters have a specific style… and if they deviate from that, they may get beaten. The same goes for trading, in my opinion. That’s one common pitfall I fell into when I first started trading. I basically traded whatever moved. However, I knew in order to become a better trader, I needed to [set some guidelines for myself and find an edge](. That’s when I developed strategies that focused on catalysts. In other words, I looked for reasons why a stock would move. Thereafter, I created a concise trading plan and executed… and that’s when I started to become profitable. To this day, [I still follow the same approach](. The thing is, I know the struggles of being a trader with a small account… and [the one thing I wish I knew when I first started was to take things slow and just focus on one trade idea a week](. Let me show you how it works. Case Study: My One Trade A Week Strategy The strategy I’m using is called [Fast 5 Trades](. Let me show you how it works. It all starts with an idea. Thereafter, I look for key areas where I believe it’s advantageous to buy and take profits… I also know where I want to stop out, in case things go against me. My goal is to generate double-digit percentage returns (or more) in 5 days or less. Here’s how one of those trade ideas look... [Alternate text]( As you can see above, I had a thesis… and the catalyst here was the company was working on a Covid-19 vaccine at the time. On the chart, it looked strong to me. Basically, the bull flag pattern was forming and I was looking for a move higher. [Alternate text] Chart Courtesy of [StockCharts]( Shortly after I made my moves in INO, here’s what happened with the stock… [Alternate text] Chart Courtesy of [StockCharts]( I was able to lock in a quick 6.85% winner and played it safe. [Alternate text]( When traders focus on just one trade idea (or a handful) with an edge, I believe it can help to avoid style drifting. If you want to find out how [Fast 5 Trades]( works and take it for a spin, then [click here and check out this exclusive offer](. Kyle Dennis [Special]( RagingBull, LLC 62 Calef Hwy. #233, Lee, NH 03861 [Click Here to stop receiving emails from kyle@biotechbreakouts.com]( [Unsubscribe from all RagingBull emails]( Neither Kyle Dennis nor RagingBull.com, LLC (publisher of BiotechBreakouts) is registered as an investment adviser nor a broker/dealer with either the U. S. Securities & Exchange Commission or any state securities regulatory authority. Users of this website are advised that all information presented on this website is solely for informational purposes, is not intended to be used as a personalized investment recommendation, and is not attuned to any specific portfolio or to any user's particular investment needs or objectives. The owners, employees and writers of RagingBull.com may engage in securities trading that is discussed or viewed on this website, but all such individuals are buying and selling such securities for their own account. These individuals do not engage in any trades with customers. The buying and selling of securities by these individuals is not part of a regular business of buying and selling securities. Past performance is NOT indicative of future results. Furthermore, such information is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell (short or otherwise) any security. All users of this website must determine for themselves what specific investments to make or not make and are urged to consult with their own independent financial advisors with respect to any investment decision. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. All opinions, analyses and information included on this website are based on sources believed to be reliable and written in good faith, but should be independently verified, and no representation or warranty of any kind, express or implied, is made, including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. In addition, we undertake no responsibility to notify such opinions, analyses or information or to keep such opinions, analyses or information current. Also be aware that owners, employees and writers of and for RagingBull.com, LLC may have long or short positions in securities that may be discussed on this website or newsletter, but all such positions are held for such representative’s own account. Past results are not indicative of future profits. This table is accurate, though not every trade is represented. Profits and losses reported are actual figures from the portfolios Kyle Dennis manages on behalf of RagingBull.com, LLC. If you have a current active subscription with Biotech Breakouts you will need to contact us here if you want to cancel your subscription. Opting out of emails does not remove you from your service at BiotechBreakouts.com.

Marketing emails from biotechbreakouts.com

View More
Sent On

31/07/2021

Sent On

31/07/2021

Sent On

17/07/2021

Sent On

09/07/2021

Sent On

08/07/2021

Sent On

08/07/2021

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.